KAPOSI'S SARCOMA HERPESVIRUS AS TARGET FOR IMMUNOTHERAPY IN MULTIPLE MYELOMA

$109,507P01FY2002CANIH

Dana-Farber Cancer Institute, Boston MA

Investigators

Linked publications & trials

Paper 34301753 Paper 32060401 Paper 31332296 Paper 31277554 Paper 31182781 Paper 30135465 Paper 30026574 Paper 29487385 Paper 29089645 Paper 29048129 Paper 28643330 Paper 28490812 Paper 28487543 Paper 28249894 Paper 28151709 Paper 28126925 Paper 28107546 Paper 28082445 Paper 27928025 Paper 27418644 Paper 27347699 Paper 27287071 Paper 27196750 Paper 27127303 Paper 27118409 Paper 27118403 Paper 27098276 Paper 26907633 Paper 26883876 Paper 26728187 Paper 26630652 Paper 26527748 Paper 26456076 Paper 26370838 Paper 26338273 Paper 26118499 Paper 26080835 Paper 25979485 Paper 25978432 Paper 25634684 Paper 25538258 Paper 25513470 Paper 25306900 Paper 25181531 Paper 25139740 Paper 25113767 Paper 24962017 Paper 24935722 Paper 24934808 Paper 24859877 Paper 24813251 Paper 24761838 Paper 24732597 Paper 24632713 Paper 24580102 Paper 24481412 Paper 24476765 Paper 24429703 Paper 24429336 Paper 24319254 Paper 24292625 Paper 24150220 Paper 24135401 Paper 24127452 Paper 24088394 Paper 24078774 Paper 24032635 Paper 24018393 Paper 24013749 Paper 23925045 Paper 23913134 Paper 23912587 Paper 23897982 Paper 23867470 Paper 23750791 Paper 23733782 Paper 23685836 Paper 23647456 Paper 23589314 Paper 23588715 Paper 23584492 Paper 23582718 Paper 23554930 Paper 23522020 Paper 23515406 Paper 23510648 Paper 23475757 Paper 23454749 Paper 23446999 Paper 23418540 Paper 23409060 Paper 23372151 Paper 23333523 Paper 23321256 Paper 23321251 Paper 23320055 Paper 23298856 Paper 23293352 Paper 23287861 Paper 23240658

Abstract

The recently identified gamma herpesvirus, Kaposi's sarcoma herpesvirus or KSHV, has been associated with multiple neoplasms including Kaposi's sarcoma, non-Hodgkin's lymphoma, Castleman's disease and multiple myeloma. The role of KSHV in transformation is not clear, but clinical data strongly support the role of immunologic competence in controlling KSHV- related disease in transplant or AIDS-related KS. Therefore, characterization of the cellular immune response to KSHV may provide the basis for immunologic interventions to treat and prevent KSHV-related cancer. The identification of KSHV may provide the basis for immunologic interventions to treat and prevent KSHV-related cancer. The identification of KSHV in multiple myeloma bone marrow stromal cells, but not in MGUS or other disorders has provided a highly exploitable target for immune based therapies. The hypothesis that KSHV is linked top multiple myeloma will be analyzed in detail focusing on the characterization of the immune response to KSHV in myeloma to generate specific immunologic strategies to treat and/or prevent this disease. Specifically, we propose. 1. To further define and characterize KSHV in multiple myeloma. 2. To assess CTL response to KSHV in myeloma and the prodromal condition, MGUS. 3. To assess KSHV-specific CD4 helper cell responses in myeloma and MGUS.

View original record on NIH RePORTER →